Mirum CFO awarded options and stock units

Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt received new equity awards on January 28, 2026.

Rhea-AI Filing Summary

Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt received new equity awards on January 28, 2026. He was granted stock options for 18,140 shares of common stock at an exercise price of $100.85 per share, plus 11,760 restricted stock units and 20,000 performance-based restricted stock units.

The stock options vest over four years, with one-quarter vesting one year after January 28, 2026 and the remainder in 36 equal monthly installments. The restricted stock units vest in three equal annual installments from the same date. The performance units vest two-thirds on March 15, 2026 and one-third on March 15, 2027 after performance criteria were met.

Insider Trade Summary

Grant/Award: 49,900 shares

Grant/Award 3 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	18,140	$0.00	$0.00
Grant/Award	Restricted Stock Units	11,760	$0.00	$0.00
Grant/Award	Performance Restricted Stock Units	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 18,140 contracts (Direct); Restricted Stock Units — 11,760 contracts (Direct); Performance Restricted Stock Units — 20,000 contracts (Direct)

Footnotes (4)

1. F1. 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
2. F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
3. F3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.
4. F4. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

FAQ

What insider transaction did Mirum Pharmaceuticals (MIRM) report for its CFO?

Mirum Pharmaceuticals (MIRM) reported that its chief financial officer, Eric Bjerkholt, received equity awards on January 28, 2026. These included stock options, restricted stock units, and performance-based restricted stock units, all reported as directly owned following the transactions on that date.

How many stock options did the Mirum (MIRM) CFO receive and at what exercise price?

The Mirum (MIRM) chief financial officer received 18,140 stock options on January 28, 2026. These options relate to common stock and carry a conversion or exercise price of $100.85 per share, with vesting occurring over a four-year period from the vesting commencement date.

What restricted stock unit grants were reported for Mirum (MIRM) CFO Eric Bjerkholt?

Eric Bjerkholt received 11,760 restricted stock units on January 28, 2026, each representing a contingent right to one Mirum (MIRM) common share. One-third of these restricted stock units vest on each anniversary of January 28, 2026, so the entire award vests over three years.

How are the Mirum (MIRM) CFO’s stock options scheduled to vest?

One-quarter of the CFO’s stock options vest one year after January 28, 2026, the vesting commencement date. The remaining shares then vest in 36 successive equal monthly installments starting from the first anniversary, creating a four-year total vesting period for the option grant.

What are the terms of the performance restricted stock units granted at Mirum (MIRM)?

Performance restricted stock units covering 20,000 shares were granted earlier and became eligible to vest after performance criteria were determined met on January 28, 2026. Two-thirds of these shares vest on March 15, 2026, and the remaining one-third vest on March 15, 2027.

Does the Mirum (MIRM) Form 4 show direct or indirect ownership for these awards?

All three awards reported—stock options, restricted stock units, and performance restricted stock units—are listed as directly owned by the reporting person. The ownership form column identifies each position as “D” for direct, with no separate nature of indirect beneficial ownership disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$100.85	01/28/2026		A		18,140		(1)	01/27/2036	Common Stock	18,140	$0	18,140	D
Restricted Stock Units	(2)	01/28/2026		A		11,760		(3)	(3)	Common Stock	11,760	$0	11,760	D
Performance Restricted Stock Units	(2)	01/28/2026		A		20,000		(4)	(4)	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

4. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.